Brown: Risk Weighti...
Health Care: Drugs
OxiGene Inc. (OXGN: NASDAQ)
$3.30 0.07 | 2.06%
05/17/13 - 03:39 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -8.08M | -9.65M | -23.77M | -24.73M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 55.00K | 65.00K | -140.00K |
| (Decrease) Increase In Payables | -1.35M | -956.00K | -4.34M | 1.85M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 505.00K | -1.37M | 6.97M | -5.66M |
| Net Cash From Continuing Operations | -8.34M | -11.78M | -20.43M | -28.67M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.34M | -11.78M | -20.43M | -28.67M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 4.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 753.00K |
| Purchases of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | -109.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -8.00K | 0.00 | 3.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -8.00K | 0.00 | 3.00K | 2.93M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 3.32M | 17.15M | 11.04M | 9.03M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 50.00K | 12.36M |
| Net Cash From Financing Activities | 3.32M | 17.15M | 11.09M | 21.39M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -5.03M | 5.37M | -9.33M | -4.34M |
Portfolios with OXGN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorSmall-Cap Stocks in Danger ...
- UserMy Portfolio
- UserMy Portfolio
- Contributor5 Drug Stock Losers of 2010
- UserASCO 2010 Part 2
- UserBIN
- UserJBOND Portfolio 1
- UserASCO 2009 Nymph's Watch List.
Latest OXGN Headlines from TheStreet
- OXiGENE Reports First Quarter 2013 Financial Results 05.06.13 | 04:05 pm
- OXiGENE Announces Completion Of Enrollment Of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial 04.24.13 | 04:04 pm
- OXiGENE Announces First Quarter 2013 Earnings Conference Call And Webcast 04.24.13 | 06:04 am
- OXiGENE Announces $5 Million Private Placement 04.11.13 | 08:04 am
- OXiGENE Announces Issuance Of Patent For Benzosuberenes, A Novel Anticancer Class Of Agents 03.20.13 | 04:03 pm
- OXiGENE Reports Full Year 2012 Financial Results 03.12.13 | 04:03 pm
- OXiGENE Announces Year-End 2012 Earnings Conference Call And Webcast 03.04.13 | 02:03 pm
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues To Be Well Tolerated In Second Interim Toxicity Analysis Of A Phase 2 Ovarian Cancer Trial 02.06.13 | 04:02 pm
- 3 Stocks Under $5 Making Big Moves 02.05.13 | 02:02 pm
Press Releases for OXGN
Partner Headlines for OXGN
- OXiGENE Announces Changes to Board of Directors - Benzinga 09.09.11 | 04:09 pm
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- ZYBRESTAT Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer - Benzinga 06.06.11 | 04:06 pm
- Morning Market Movers - Benzinga 06.06.11 | 09:06 am
- 7 Big Movers That Investors Must Watch This Week - Seeking Alpha 06.06.11 | 08:06 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- UPDATE 1-Oxigene reports positive data on cancer drug - Reuters 10.11.10 | 08:10 am
- Three Promising Small-Cap Cancer Plays - Seeking Alpha 05.17.10 | 08:05 am
- UPDATE 1-Oxigene says auditors raise going concern doubts - Reuters 03.19.10 | 08:03 am
- UPDATE 1-Oxigene to cut half the jobs, sees Q1 charge - Reuters 02.11.10 | 11:02 am
